---
document_datetime: 2025-10-30 13:19:43
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/orkambi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: orkambi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 17.3254092
conversion_datetime: 2025-12-23 02:53:27.714418
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Orkambi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | Notification acc.Article61(3)-Accepted | 30/10/2025                          |                                          | PL                              |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000308598                      | Update of the package leaflet to delete the list ofcontactdetailsof local representatives.                                                                                                                                                                                                                                                                                                                                                                                              |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 5 year/ EMA/R/0000249341    | - Renewal - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 24/07/2025 | 17/09/2025 | SmPC and PL | Based on the review of data on quality, safety and efficacy,theCHMPconsideredthatthebenefit-risk balanceofOrkambi intheapprovedindication remainsfavourableandthereforerecommendedthe renewal of themarketing authorisationwith unlimited validity.                                                                                                                                                                                                                                                          |
| Variation type IB / EMA/VR/0000265388 | B.II.f.1.bExtension of the shelf life of the finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted                                                                                                                                                                                                                                                                                                                                              | 11/07/2025 | 17/09/2025 | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Variation type II / EMA/VR/0000250205 | C.I HUMANANDVETERINARY MEDICINAL PRODUCTS-C.I.4 Change(s) in the Summary of Product Characteristics, LabellingorPackageLeafletduetonew quality, preclinical, clinical or pharmacovigilancedata-Accepted Updateofsection4.8of theSmPCinorder to update information on adverse drug reactions(ADRs)in paediatricpopulation and to align it with Company Core Data Sheet (CCDS) based on clinical safety results fromstudy809-124whichweresubmitted undervariationEMEA/H/C/003954/I1/0088. | 26/06/2025 | 17/09/2025 | SmPC        | The proposed text to be included in the section 4.8 (AdverseEvents-Paediatricpopulation)is as follows:\"Long-term safetydatafrom a96-week extensionstudy(trial809-124)in52patients aged 1 year and older(39rolledoverfrom trial 809-122 and13Orkambinaivepatients)whowere homozygousfortheF508delmutationintheCFTR gene were generally consistent with the 24-week parent study in patients aged 1 to less than 2 years (trial809-122).\"For more information,pleaserefer totheSummaryofProductCharacteristics |

<div style=\"page-break-after: always\"></div>